Cargando…

Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas

Introduction: Despite advances in comprehending cancer biology, malignant gliomas remain incurable. The present work conducted a multi-omics analysis for investigating the significance of chloride intracellular channel 1 (CLIC1) in gliomas. Methods: Multi-omics data of glioma covering transcriptomic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengcheng, He, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663228/
https://www.ncbi.nlm.nih.gov/pubmed/38027011
http://dx.doi.org/10.3389/fphar.2023.1279370
_version_ 1785138352129835008
author Wang, Chengcheng
He, Zheng
author_facet Wang, Chengcheng
He, Zheng
author_sort Wang, Chengcheng
collection PubMed
description Introduction: Despite advances in comprehending cancer biology, malignant gliomas remain incurable. The present work conducted a multi-omics analysis for investigating the significance of chloride intracellular channel 1 (CLIC1) in gliomas. Methods: Multi-omics data of glioma covering transcriptomics, genomics, DNA methylation and single-cell transcriptomics from multiple public cohorts were enrolled for analyzing CLIC1. In vitro experiments were conducted to measure apoptosis and cell mobility in U251 and U373 glioma cells following transfection of CLIC1 siRNAs. Results: Elevated CLIC1 expression was proven to stably and independently estimate worse survival outcomes. CLIC1 expression was higher in more advanced stage, wild-type IDH and unmethylated MGMT samples. Tumorigenic and anticancer immunity pathways were remarkably enriched in CLIC1-up-regulated tumors. Additionally, CLIC1 was positively linked with cancer-immunity cycle, stromal activation, DNA damage repair and cell cycle. Suppressing CLIC1 resulted in apoptosis and attenuated cell motility of glioma cells. More frequent genomic alterations were found in CLIC1-up-regulated tumors. CLIC1 expression presented a remarkably negative connection to DNA methylation. High CLIC1 expression samples were more sensitive to camptothecin, cisplatin, doxorubicin, erlotinib, paclitaxel, rapamycin, clofarabine, tanespimycin, methotrexate, everolimus, TAK-733, trametinib and AZD8330. Tumors with upregulated CLIC1 presented abundant immune cell infiltration, higher expression of immune-checkpoints and -modulators and similar transcriptome profiling, indicative of well response to immune-checkpoint blockade (ICB). Nevertheless, due to elevated TIDE score, tumors with CLIC1 upregulation appeared to be resistant to ICB. Single-cell analysis unveiled that CLIC1 was expressed ubiquitously in tumor cells and tumor microenvironment. Conclusions: Overall, CLIC1 was a promising treatment vulnerability in glioma.
format Online
Article
Text
id pubmed-10663228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106632282023-11-08 Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas Wang, Chengcheng He, Zheng Front Pharmacol Pharmacology Introduction: Despite advances in comprehending cancer biology, malignant gliomas remain incurable. The present work conducted a multi-omics analysis for investigating the significance of chloride intracellular channel 1 (CLIC1) in gliomas. Methods: Multi-omics data of glioma covering transcriptomics, genomics, DNA methylation and single-cell transcriptomics from multiple public cohorts were enrolled for analyzing CLIC1. In vitro experiments were conducted to measure apoptosis and cell mobility in U251 and U373 glioma cells following transfection of CLIC1 siRNAs. Results: Elevated CLIC1 expression was proven to stably and independently estimate worse survival outcomes. CLIC1 expression was higher in more advanced stage, wild-type IDH and unmethylated MGMT samples. Tumorigenic and anticancer immunity pathways were remarkably enriched in CLIC1-up-regulated tumors. Additionally, CLIC1 was positively linked with cancer-immunity cycle, stromal activation, DNA damage repair and cell cycle. Suppressing CLIC1 resulted in apoptosis and attenuated cell motility of glioma cells. More frequent genomic alterations were found in CLIC1-up-regulated tumors. CLIC1 expression presented a remarkably negative connection to DNA methylation. High CLIC1 expression samples were more sensitive to camptothecin, cisplatin, doxorubicin, erlotinib, paclitaxel, rapamycin, clofarabine, tanespimycin, methotrexate, everolimus, TAK-733, trametinib and AZD8330. Tumors with upregulated CLIC1 presented abundant immune cell infiltration, higher expression of immune-checkpoints and -modulators and similar transcriptome profiling, indicative of well response to immune-checkpoint blockade (ICB). Nevertheless, due to elevated TIDE score, tumors with CLIC1 upregulation appeared to be resistant to ICB. Single-cell analysis unveiled that CLIC1 was expressed ubiquitously in tumor cells and tumor microenvironment. Conclusions: Overall, CLIC1 was a promising treatment vulnerability in glioma. Frontiers Media S.A. 2023-11-08 /pmc/articles/PMC10663228/ /pubmed/38027011 http://dx.doi.org/10.3389/fphar.2023.1279370 Text en Copyright © 2023 Wang and He. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Chengcheng
He, Zheng
Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title_full Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title_fullStr Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title_full_unstemmed Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title_short Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas
title_sort multi-omics analysis reveals clic1 as a therapeutic vulnerability of gliomas
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663228/
https://www.ncbi.nlm.nih.gov/pubmed/38027011
http://dx.doi.org/10.3389/fphar.2023.1279370
work_keys_str_mv AT wangchengcheng multiomicsanalysisrevealsclic1asatherapeuticvulnerabilityofgliomas
AT hezheng multiomicsanalysisrevealsclic1asatherapeuticvulnerabilityofgliomas